Cardiac Organoid Co-Culture System for CHIP Mutation Modeling

Solution Overview

Problem

Current technologies lack an effective model for simulating the interaction between myeloid/lymphoid/hematopoietic stem cells and cardiac tissue to study the impact of CHIP-related mutations on heart health, which is crucial for drug screening and understanding cardiovascular diseases.

Innovation Solution

A cardiac cell culture model system is developed, comprising cardiac organoids and myeloid, lymphoid, or hematopoietic cells, allowing for co-culture and genetic modification to assess the biological interactions, infiltration, and phenotypic effects, enabling the evaluation of pharmaceutical compounds' impact on these interactions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a dual-component co-culture system is established to model CHIP interactions, then the biological realism and disease modeling capability are improved, but the device complexity and operational difficulty increase

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The system is segmented into distinct modular components: cardiac organoids in lower wells and hematopoietic cells in upper wells of a Transwell insert system. This segmentation allows independent preparation and maintenance of each cell type while enabling controlled interaction through defined interfaces (membrane pores), thereby improving reliability without overwhelming complexity

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The Transwell insert membrane acts as an intermediary structure that facilitates controlled interaction between cardiac organoids and hematopoietic cells. The membrane allows selective passage of cells and molecules while maintaining physical separation, enabling realistic CHIP interaction modeling through a manageable intermediate component

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If genetic modifications are introduced to hematopoietic cells to model CHIP mutations, then the specificity and accuracy of disease modeling are improved, but the manufacturing complexity and time requirements increase

Engineering Contradiction:
Core Design Contradiction:
Measurement precisionVSEase of manufacture

Solution Approach 1:

Genetic modifications (CRISPR/Cas9, transduction) are performed on hematopoietic cells in advance before co-culture establishment. Cells are genetically engineered, validated, and expanded separately, allowing sufficient time for complex genetic manipulation without delaying the overall experiment. Pre-modified cells are then ready for immediate co-culture with cardiac organoids

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

Standardized genetic modification protocols and validated cell lines are used to create consistent CHIP models. Once a genetic modification protocol is established for a particular mutation, it can be replicated across multiple experiments and laboratories, reducing manufacturing complexity through proven copyable methods

Inventive Principle:
Principle #26Copying

3Duration of action of moving object

If long-term co-culture maintenance is implemented to study chronic CHIP effects, then the duration and depth of biological interaction assessment are improved, but the operational burden and resource consumption increase

Engineering Contradiction:
Core Design Contradiction:
Duration of action of moving objectVSEase of operation

Solution Approach 1:

The Transwell co-culture system is designed to maintain continuous biological interaction between hematopoietic cells and cardiac organoids over extended periods (weeks to months). The modular design allows for sustained co-culture with periodic media changes and monitoring, enabling chronic CHIP effect studies without requiring constant intervention or re-establishment of interactions

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The co-culture system is designed to maintain itself with minimal intervention. Once established, the system sustains cell viability and interactions through its own microenvironment, requiring only periodic media changes. The structural design (Transwell inserts, organoid containment) maintains physical organization automatically, reducing operational burden during long-term culture

Inventive Principle:
Principle #25Self-service

Data Source

PatentUS20240110155A1A dual cardiac-blood model system for disease modelling and drug screening
Publication Date: 2024.04.04
  • US20240110155A1 patent drawing
  • US20240110155A1 patent drawing
  • US20240110155A1 patent drawing

AI summary

The present invention relates to a cardiac cell culture model system composed of a cardiac organoid and blood or blood precursor cells. The cardiac cell culture model system serves as a model for the heart, and the present invention also relates to drug screening with the cardiac cell culture model system investigating the impact of the drug on the heart.